Enveric Biosciences completes PK EB-003 studies

Enveric Biosciences (ENVB) announced the completion of preclinical pharmacokinetic, or PK, studies in rat and dog further supporting the oral bioavailability and targeted non-hallucinogenic profile of EB-003. The PK studies demonstrated oral bioavailability in rat and dog studies that was dose-proportional, as was also shown previously in a mouse model. No clinical signs, including those associated with hallucination, were observed in either study. For example, in dogs, ataxia and vocalization were not observed. Additionally, significant brain penetration was demonstrated in the rat model with a brain/plasma ratio of about 5-6, which is significantly higher than was seen in the mouse model. This increased brain/plasma ratio could translate to enhanced efficacy, lower doses, and less off-target side effects if these findings are confirmed in clinical trials.